The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors

Improved donor/acceptor BRET couples for monitoring β-arrestin recruitment to G protein-coupled receptors

(2009) Maud Kamal et al.   Biotechnology Journal

Improving antidepressant drugs: update on recently patented compounds

(2009) Isabel Rozas   EXPERT OPINION ON THERAPEUTIC PATENTS

Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice

(2009) Eleni Païzanis et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome

(2009) Guy M. Goodwin et al.   JOURNAL OF CLINICAL PSYCHIATRY

Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus

(2009) Amélie Soumier et al.   NEUROPSYCHOPHARMACOLOGY

Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture

(2009) Amandine Descamps et al.   PSYCHOPHARMACOLOGY

Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action

(2009) Siegfried Kasper et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Pharmacology of 5HT2C receptor-mediated ERK1/2 phosphorylation: Agonist-specific activation pathways and the impact of RNA editing

(2008) Tim D. Werry et al.   BIOCHEMICAL PHARMACOLOGY

Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells

(2008) Didier Cussac et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Circadian rhythm disturbances in depression

(2008) Anne Germain et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Activation of 5-HT2A/CReceptors Counteracts 5-HT1ARegulation ofN-Methyl-D-aspartate Receptor Channels in Pyramidal Neurons of Prefrontal Cortex

(2008) Eunice Y. Yuen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy of Agomelatine in Generalized Anxiety Disorder

(2008) Dan J. Stein et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Serotonin 5-HT2B Receptors Are Required for 3,4-Methylenedioxymethamphetamine-Induced Hyperlocomotion and 5-HT Release In Vivo and In Vitro

(2008) S. Doly et al.   JOURNAL OF NEUROSCIENCE

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale

(2008) AL Montejo et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Physical Interaction of Calmodulin with the 5-Hydroxytryptamine2C Receptor C-Terminus Is Essential for G Protein-independent, Arrestin-dependent Receptor Signaling

(2008) Marilyne Labasque et al.   MOLECULAR BIOLOGY OF THE CELL

Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors

(2008) Christopher S. Knauer et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors

(2008) V.J. Aloyo et al.   PHARMACOLOGY & THERAPEUTICS

Agonist-directed signaling of the serotonin 2A receptor depends on  -arrestin-2 interactions in vivo

(2008) C. L. Schmid et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

(2008) Anne Dekeyne et al.   PSYCHOPHARMACOLOGY

Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation

(2008) Baoman Li et al.   PSYCHOPHARMACOLOGY

Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions

(2008) M MILLAN et al.   TRENDS IN PHARMACOLOGICAL SCIENCES